ALLN 177

Drug Profile

ALLN 177

Alternative Names: ALLN-177; Oxalate decarboxylase - Allena Pharmaceuticals

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allena Pharmaceuticals
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperoxaluria
  • Preclinical Primary hyperoxaluria

Most Recent Events

  • 06 Mar 2018 Phase-III clinical trials in Hyperoxaluria in USA (PO) (NCT03456830)
  • 06 Mar 2018 Allena Pharmaceuticals plans the phase III URIROX-2 trial (formerly Study 302) for Hyperoxaluria in USA in the second half of 2018
  • 14 Dec 2017 Allena Pharmaceuticals plans to initiate a Phase II trial in Primary hyperoxaluria (In adolescents, In adults) in Q1 2018 (PO, Capsule) (NCT03391804)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top